Trial Profile
A phase I trial to investigate the safety, tolerability and pharmacokinetics of remeglurant (MRZ8456) for the treatment of late complications in Parkinson's disease
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 May 2016
Price :
$35
*
At a glance
- Drugs Remeglurant (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions; First in man
- 06 May 2016 New trial record